Donanemab, the newly FDA-approved Alzheimer’s drug, offers monthly infusion treatment that slows early cognitive decline by ...

Donanemab – one of the first drugs to slow down early-stage Alzheimer’s disease – will not be available on the NHS in ...

In 2024, the European Medicines Agency (EMA) approved lecanemab for the treatment of early Alzheimer's disease in patients without contraindications or risk factors for side-effects. This approval ...

Lecanemab and donanemab (Kisunla), another anti-amyloid treatment, won approval based on evidence that they slowed cognitive ...

Campaigners have called for a change in the way treatments for dementia are assessed in the wake of the decision on the drug ...

At that level, both lecanemab and donanemab act very similarly. "Further work is needed to understand what is most important: binding oligomeric structures or binding amyloid plaques. This is ...

In a real-world study, infusion-related reactions occurred in 37% of Alzheimer's patients treated with lecanemab. Amyloid-related imaging abnormalities (ARIA) emerged in 22% of treated patients.

An estimated 7.2 million Americans aged 65 years and older are living with Alzheimer dementia, and almost all adults feel it is important to diagnose the disease in the early stages.

Donanemab, made by Eli Lilly and sold under the brand name Kisunla, is not a cure, nor can it reverse memory loss, doctors say. But research has shown that, like its predecessor lecanemab ...